Kyoung Mee Kim

List of Publications by Year
in descending order

329	14,827	25034	27406
papers	citations	57 h-index	106 g-index

337	337	337	17553
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. European Radiology, 2022, 32, 1-11.	4.5	6
2	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2427-2435.	2.5	5
3	Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer. Clinical and Translational Oncology, 2022, 24, 556-567.	2.4	11
4	Two Gastric Cancers With Uncommon ALK Fusion Diagnosed With Comprehensive Panel Sequencing and Confirmed With Companion Diagnostic Assay. AJSP Review and Reports, 2022, 27, 9-12.	0.1	0
5	Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers. BMC Medical Genomics, 2022, 15, 25.	1.5	3
6	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. Biomedicines, 2022, 10, 543.	3.2	14
7	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. Journal of Oncology, 2022, 2022, 1-9.	1.3	7
8	Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers. Pathology Research and Practice, 2022, 233, 153874.	2.3	15
9	Early Tumorâ€“Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. Cancer Discovery, 2022, 12, 984-1001.	9.4	52
10	High Frequency of Juxtamembrane DomainERBB2Mutation in Gastric Cancer. Cancer Genomics and Proteomics, 2022, 19, 105-112.	2.0	7
11	Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma. Frontiers in Oncology, 2022, 12, 856444.	2.8	3
12	Prevalence of MET aberration using next generation sequencing in oncology clinic: A real-world experience.. Journal of Clinical Oncology, 2022, 40, e16099-e16099.	1.6	0
13	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. , 2022, 10, e005041.		31
14	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer, 2021, 24, 457-466.	5.3	34
15	MicroRNA signatures associated with lymph node metastasis in intramucosal gastric cancer. Modern Pathology, 2021, 34, 672-683.	5.5	28
16	A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trialâ€†. Annals of Oncology, 2021, 32, 368-374.	1.2	153
17	Digital image analysis in pathologistâ€selected regions of interest predicts survival more accurately than wholeâ€slide analysis: a direct comparison study in 153 gastric carcinomas. Journal of Pathology: Clinical Research, 2021, 7, 42-51.	3.0	6
18	DNA-protein biomarkers for immunotherapy in the era of precision oncology. Journal of Pathology and Translational Medicine, 2021, 55, 26-32.	1.1	2

#	Article	IF	Citations
19	Gastric Inverted Polypsâ€"Distinctive Subepithelial Lesions of the Stomach. American Journal of Surgical Pathology, 2021, 45, 680-689.	3.7	8
20	PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study. Pathology Research and Practice, 2021, 218, 153338.	2.3	12
21	Clinical feasibility and oncologic safety of primary endoscopic submucosal dissection for clinical submucosal invasive early gastric cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3051-3061.	2.5	1
22	Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma. Gastric Cancer, 2021, 24, 858-867.	5.3	23
23	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instabilityâ€"High Gastric Cancer. Cancer Discovery, 2021, 11, 2168-2185.	9.4	105
24	Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).. Journal of Clinical Oncology, 2021, 39, 3536-3536.	1.6	5
25	PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. Modern Pathology, 2021, 34, 1719-1727.	5.5	48
26	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical Cancer Research, 2021, 27, 4700-4709.	7.0	54
27	Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. Cancers, 2021, 13, 2316.	3.7	5
28	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. Frontiers in Immunology, 2021, 12, 701668.	4.8	13
29	Prognostic Value of Highly Expressed Type VII Collagen (COL7A1) in Patients With Gastric Cancer. Pathology and Oncology Research, 2021, 27, 1609860.	1.9	13
30	Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. , 2021, 9, e002467.		97
31	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. Annals of Surgical Oncology, 2021, 28, 8908-8915.	1.5	4
32	ASO Video Abstract: Microsatellite Instability and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancerâ€"A Multi-cohort Study. Annals of Surgical Oncology, 2021, 28, 688.	1.5	0
33	Deep learning-based virtual cytokeratin staining of gastric carcinomas to measure tumorâ€"stroma ratio. Scientific Reports, 2021, 11, 19255.	3.3	10
34	PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. Cancers, 2021, 13, 4659.	3.7	20
35	Highly sensitive duplex MSI test and BAT40 germline polymorphism. Apmis, 2021, 129, 607-615.	2.0	4
36	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199299.	3.2	20

#	Article	IF	Citations
37	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. Genome Medicine, 2021, 13, 11.	8.2	17
38	Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 583-591.	2.2	2
39	Risk-Scoring System for Prediction of Non-Curative Endoscopic Submucosal Dissection Requiring Additional Gastrectomy in Patients with Early Gastric Cancer. Journal of Gastric Cancer, 2021, 21, 368.	2.5	2
40	Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. European Journal of Surgical Oncology, 2020, 46, 189-194.	1.0	10
41	Outcomes of endoscopic submucosal dissection for intestinalâ€type adenocarcinoma with anastomosing glands of the stomach. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 50-55.	2.8	3
42	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 243-250.	2.8	16
43	Correlation between RICTOR overexpression and amplification in advanced solid tumors. Pathology Research and Practice, 2020, 216, 152734.	2.3	6
44	PTEN Protein losses and loss-of-function genetic variants in gastric cancers: the relationship with microsatellite instability, EBV, and PD-L1 expression. Pathology, 2020, 52, S120.	0.6	0
45	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. Radiotherapy and Oncology, 2020, 152, 19-25.	0.6	9
46	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092679.	3.2	9
47	IL-7RÎ±low CD8+ T Cells from Healthy Individuals Are Anergic with Defective Glycolysis. Journal of Immunology, 2020, 205, 2968-2978.	0.8	5
48	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Translational Cancer Research, 2020, 9, 3367-3374.	1.0	26
49	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. Frontiers in Oncology, 2020, 10, 225.	2.8	7
50	Circulating Antibodies against Epsteinâ€“Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 414-419.	2.5	8
51	PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression. Cancers, 2020, 12, 1724.	3.7	13
52	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. Pathology Research and Practice, 2020, 216, 152820.	2.3	6
53	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. Journal of Oncology, 2020, 2020, 1-8.	1.3	7
54	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathology Research and Practice, 2020, 216, 152881.	2.3	67

#	Article	IF	Citations
55	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathology Research and Practice, 2020, 216, 152878.	2.3	21
56	Comprehensive pharmacogenomic characterization of gastric cancer. Genome Medicine, 2020, 12, 17.	8.2	20
57	Interchangeability of PD-L1 laboratory-developed test by 22C3 antibody concentrate among ihc platforms in gastric cancer. Pathology, 2020, 52, S120.	0.6	1
58	Dysregulated miRNA in a cancer-prone environment: A study of gastric non-neoplastic mucosa. Scientific Reports, 2020, 10, 6600.	3.3	3
59	CDH1 mutations in gastric cancers are not associated with family history. Pathology Research and Practice, 2020, 216, 152941.	2.3	4
60	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. Cancers, 2020, 12, 943.	3.7	5
61	Favorable Long-Term Outcomes of Endoscopic Submucosal Dissection for Differentiated-Type-Predominant Early Gastric Cancer with Histological Heterogeneity. Journal of Clinical Medicine, 2020, 9, 1064.	2.4	3
62	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. Frontiers in Oncology, 2020, 10, 314.	2.8	62
63	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer. JCO Precision Oncology, 2020, 4, 222-232.	3.0	16
64	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. Pathology Research and Practice, 2020, 216, 152947.	2.3	11
65	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. Cancer Research and Treatment, 2020, 52, 1153-1161.	3.0	9
66	Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.. Journal of Clinical Oncology, 2020, 38, e16541-e16541.	1.6	0
67	Abstract 2370: Elevated levels of anti-Epstein Barr virus (EBV) antibodies in EBV-associated gastric carcinoma. , 2020, , .		0
68	Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. Gastric Cancer, 2019, 22, 363-368.	5.3	22
69	Gastrointestinal stromal tumour with CDKN2A deletions: a report of three cases. Pathology, 2019, 51, 537-539.	0.6	0
70	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clinical Cancer Research, 2019, 25, 7035-7045.	7.0	152
71	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. Journal of Cancer, 2019, 10, 3172-3178.	2.5	9
72	Gastric adenocarcinoma with enteroblastic differentiation should be differentiated from hepatoid adenocarcinoma: A study with emphasis on clear cells and clinicopathologic spectrum. Pathology Research and Practice, 2019, 215, 152525.	2.3	12

#	Article	IF	Citations
73	Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue. Scientific Reports, 2019, 9, 9675.	3.3	7
74	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discovery, 2019, 9, 1388-1405.	9.4	155
75	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. Translational Oncology, 2019, 12, 1488-1495.	3.7	6
76	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	1.6	293
77	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Translational Oncology, 2019, 12, 597-601.	3.7	8
78	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2019, 21, 612-622.	2.8	9
79	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. Pathology Research and Practice, 2019, 215, 152434.	2.3	22
80	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. Oncology, 2019, 97, 38-43.	1.9	26
81	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. Frontiers in Oncology, 2019, 9, 212.	2.8	20
82	Bridging genomics and phenomics of gastric carcinoma. International Journal of Cancer, 2019, 145, 2407-2417.	5.1	40
83	LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. Journal of Immunotherapy, 2019, 42, 279-283.	2.4	11
84	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. Scientific Reports, 2019, 9, 19439.	3.3	8
85	Effect of age on the clinical outcomes of patients with early gastric cancer with undifferentiated-type histology. Surgery, 2019, 165, 802-807.	1.9	3
86	Feasibility of Endoscopic Resection in Early Gastric Cancer with Lymphovascular Invasion. Annals of Surgical Oncology, 2019, 26, 449-455.	1.5	14
87	MET is overexpressed in microsatellite instability-high gastric carcinoma. Pathology Research and Practice, 2019, 215, 433-438.	2.3	10
88	MMR protein immunohistochemistry and microsatellite instability in gastric cancers. Pathology, 2019, 51, 110-113.	0.6	20
89	Pathologic analyses of peritoneal nodules in gastric cancer patients during surgeryâ€"A single cancer center experience with diagnostic pitfalls. Pathology Research and Practice, 2019, 215, 195-199.	2.3	3
90	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. Journal of Clinical Oncology, 2019, 37, 3104-3104.	1.6	2

#	Article	IF	Citations
91	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. Journal of Clinical Oncology, 2019, 37, 4001-4001.	1.6	53
92	Epigenetic alternate promoter utilization and association with PD-L1 expression in Epsteinâ€“Barr virus positive gastric cancer.. Journal of Clinical Oncology, 2019, 37, e15509-e15509.	1.6	1
93	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. Journal of Clinical Oncology, 2019, 37, 66-66.	1.6	17
94	Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial. Precision and Future Medicine, 2019, 3, 24-29.	1.6	2
95	Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer. Precision and Future Medicine, 2019, 3, 165-175.	1.6	4
96	Inter-observer Reproducibility in the Pathologic Diagnosis of Gastric Intraepithelial Neoplasia and Early Carcinoma in Endoscopic Submucosal Dissection Specimens: A Multi-center Study. Cancer Research and Treatment, 2019, 51, 1568-1577.	3.0	12
97	Abstract 1107: LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. , 2019, , .		0
98	Abstract 3605: O-linked N-acetylglucosamine transferase as a potential therapeutic target for metastatic gastric cancer. , 2019, , .		0
99	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. American Journal of Translational Research (discontinued), 2019, 11, 4508-4515.	0.0	4
100	Abstract 3605: O-linked N-acetylglucosamine transferase as a potential therapeutic target for metastatic gastric cancer. , 2019, , .		0
101	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2018, 17, 838-848.	4.1	36
102	Characterization of Human Salivary Extracellular RNA by Next-generation Sequencing. Clinical Chemistry, 2018, 64, 1085-1095.	3.2	33
103	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open, 2018, 3, e000326.	4.5	52
104	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. Clinical Colorectal Cancer, 2018, 17, 140-146.	2.3	17
105	Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach: implications for endoscopic resection. Gastric Cancer, 2018, 21, 680-688.	5.3	22
106	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discovery, 2018, 8, 37-48.	9.4	248
107	Indication for endoscopic treatment based on the risk of lymph node metastasis in patients with Siewert type II/III early gastric cancer. Gastric Cancer, 2018, 21, 672-679.	5.3	10
108	Identification of risk factors for sessile and traditional serrated adenomas of the colon by using big data analysis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1039-1046.	2.8	16

#	Article	IF	Citations
109	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. Translational Oncology, 2018, 11, 37-42.	3.7	35
110	Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis. Journal of Clinical Pathology, 2018, 71, 221-227.	2.0	22
111	Deep Learningâ€"Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	2.1	17
112	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. Journal of Gastrointestinal Oncology, 2018, 9, 1198-1206.	1.4	6
113	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. Journal of Gastric Cancer, 2018, 18, 348.	2.5	12
114	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, 2018, 50, 1399-1411.	21.4	145
115	Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. Frontiers in Immunology, 2018, 9, 2012.	4.8	79
116	MicroRNA Expression Profiles in Gastric Carcinogenesis. Scientific Reports, 2018, 8, 14393.	3.3	65
117	Factors Associated With Host Immune Response and Number of Lymph Nodes: A Large Retrospective Cohort Study. Annals of Surgical Oncology, 2018, 25, 3621-3628.	1.5	2
118	Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. Scientific Reports, 2018, 8, 13887.	3.3	10
119	NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. Journal of Cancer, 2018, 9, 3032-3037.	2.5	22
120	Young Age and Risk of Lymph Node Metastasis in Differentiated Type Early Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2713-2719.	1.5	7
121	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine, 2018, 24, 1449-1458.	30.7	1,071
122	Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer. Clinical Chemistry, 2018, 64, 1513-1521.	3.2	56
123	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	21.4	168
124	Transcriptional analysis of immune genes in Epsteinâ€"Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer, 2018, 21, 1064-1070.	5.3	25
125	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.. Journal of Clinical Oncology, 2018, 36, 4061-4061.	1.6	3
126	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. Journal of Clinical Oncology, 2018, 36, e14501-e14501.	1.6	1

#	Article	IF	Citations
127	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.. Journal of Clinical Oncology, 2018, 36, e16029-e16029.	1.6	1
128	Peritumoral lymphoid cuff correlates well with lymph node enlargement in gastrointestinal schwannomas. Oncotarget, 2018, 9, 12591-12598.	1.8	7
129	Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer with Undifferentiated-Type Histology: A Clinical Simulation Using a Non-Selected Surgical Cohort. Gut and Liver, 2018, 12, 263-270.	2.9	10
130	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	1.6	0
131	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	1.6	0
132	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2â€“Amplified Gastric Cancer Patientâ€“Derived Cell Model. Translational Oncology, 2017, 10, 469-475.	3.7	23
133	Comparison of Long-Term Outcomes After Non-curative Endoscopic Resection in Older Patients with Early Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 2624-2631.	1.5	14
134	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	9.4	48
135	Predictive factors for lymph node metastasis in early gastric cancer with lymphatic invasion after endoscopic resection. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 4419-4424.	2.4	17
136	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. OncoImmunology, 2017, 6, e1356150.	4.6	32
137	Neurofibroma of the Colon: A Diagnostic Mimicker of Gastrointestinal Stromal Tumor. Case Reports in Gastroenterology, 2017, 10, 674-678.	0.6	10
138	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. Oncologist, 2017, 22, 1169-1177.	3.7	14
139	A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single-Nucleotide Variant Detection. Journal of Molecular Diagnostics, 2017, 19, 651-658.	2.8	21
140	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nature Communications, 2017, 8, 1377.	12.8	137
141	Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases. Histopathology, 2017, 71, 805-812.	2.9	10
142	Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine. Journal of Molecular Diagnostics, 2017, 19, 137-146.	2.8	58
143	One-dimensional and 2-dimensional tumor size measurement for prediction of lymph node metastasis in differentiated early gastric cancer with minute submucosal invasion. Gastrointestinal Endoscopy, 2017, 85, 730-736.	1.0	10
144	Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. Journal of Gastroenterology, 2017, 52, 594-601.	5.1	47

#	Article	IF	Citations
145	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. Journal of Cancer, 2017, 8, 730-736.	2.5	1
146	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). Journal of Cancer, 2017, 8, 1395-1399.	2.5	20
147	Molecular Testing for Gastrointestinal Cancer. Journal of Pathology and Translational Medicine, 2017, 51, 103-121.	1.1	54
148	Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Oncotarget, 2017, 8, 15014-15022.	1.8	42
149	Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion. Oncotarget, 2017, 8, 113758-113765.	1.8	4
150	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget, 2017, 8, 77415-77423.	1.8	68
151	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. Journal of Clinical Oncology, 2017, 35, e15610-e15610.	1.6	1
152	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget, 2017, 8, 3237-3245.	1.8	20
153	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget, 2017, 8, 13320-13328.	1.8	60
154	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer centerâ€™s experiences. Oncotarget, 2017, 8, 42478-42486.	1.8	32
155	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. Oncotarget, 2017, 8, 107492-107499.	1.8	9
156	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget, 2017, 8, 66305-66315.	1.8	23
157	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. Oncotarget, 2017, 8, 105727-105734.	1.8	16
158	MerTK is a novel therapeutic target in gastric cancer. Oncotarget, 2017, 8, 96656-96667.	1.8	23
159	IKKÎµ and TBK1 expression in gastric cancer. Oncotarget, 2017, 8, 16233-16242.	1.8	11
160	Biomarkers for gastric cancer: molecular classification revisited. Precision and Future Medicine, 2017, 1, 59-68.	1.6	25
161	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	1.6	0
162	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. Journal of Cancer, 2016, 7, 2173-2178.	2.5	1

#	Article	IF	Citations
163	The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget, 2016, 7, 7940-7951.	1.8	54
164	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. Journal of Gastric Cancer, 2016, 16, 105.	2.5	34
165	A Risk Prediction Model Based on Lymph-Node Metastasis in Poorly Differentiatedâ€“Type Intramucosal Gastric Cancer. PLoS ONE, 2016, 11, e0156207.	2.5	10
166	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489.	2.5	106
167	Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. Journal of Gastric Cancer, 2016, 16, 1.	2.5	66
168	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget, 2016, 7, 43492-43503.	1.8	45
169	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Research and Treatment, 2016, 48, 1155-1166.	3.0	142
170	Antiâ€Helicobacter pylori Antibody Profiles in Epsteinâ€Barr virus (EBV)â€Positive and EBVâ€Negative Gastric Cancer. Helicobacter, 2016, 21, 153-157.	3.5	35
171	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Modern Pathology, 2016, 29, 1095-1103.	5.5	70
172	Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor. Molecular Diagnosis and Therapy, 2016, 20, 347-351.	3.8	25
173	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. Molecular Diagnosis and Therapy, 2016, 20, 375-383.	3.8	13
174	Clinicopathological Features and Prognosis of Mixed-Type T1a Gastric Cancer Based on Laurenâ€™s Classification. Annals of Surgical Oncology, 2016, 23, 784-791.	1.5	20
175	Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor <scp>RNF43</scp> in early gastric carcinogenesis. Journal of Pathology, 2016, 240, 304-314.	4.5	44
176	The minimal amount of starting DNA for Agilentâ€™s hybrid capture-based targeted massively parallel sequencing. Scientific Reports, 2016, 6, 26732.	3.3	37
177	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open, 2016, 1, e000009.	4.5	16
178	Differential Proteomic Analysis of Human Saliva using Tandem Mass Tags Quantification for Gastric Cancer Detection. Scientific Reports, 2016, 6, 22165.	3.3	96
179	Diagnostic group classifications of gastric neoplasms by endoscopic resection criteria before and after treatment: real-world experience. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 3987-3993.	2.4	16
180	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). Journal of Cancer Research and Clinical Oncology, 2016, 142, 1231-1237.	2.5	11

#	Article	IF	Citations
181	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Clinical Cancer Research, 2016, 22, 3831-3840.	7.0	99
182	Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma. Gastric Cancer, 2016, 19, 852-859.	5.3	37
183	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trialâ€"A feasibility analysis.. Journal of Clinical Oncology, 2016, 34, 11534-11534.	1.6	3
184	Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors. Oncotarget, 2016, 7, 6538-6551.	1.8	29
185	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget, 2016, 7, 4024-4035.	1.8	36
186	Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget, 2016, 7, 13797-13809.	1.8	7
187	A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth. Oncotarget, 2016, 7, 28670-28683.	1.8	25
188	Negative Biopsy after Referral for Biopsy-Proven Gastric Cancer. Gut and Liver, 2016, 10, 63.	2.9	2
189	HER2â€positive gastric cancer with concomitant <scp>MET</scp> and/or <scp>EGFR</scp> overexpression: A distinct subset of patients for dual inhibition therapy. International Journal of Cancer, 2015, 136, 1629-1635.	5.1	33
190	The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer. Scientific Reports, 2015, 5, 9289.	3.3	43
191	Exuberant squamous metaplasia of the gastric mucosa in a patient with gastric adenocarcinoma. Diagnostic Pathology, 2015, 10, 46.	2.0	9
192	Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. British Journal of Surgery, 2015, 102, 1394-1401.	0.3	70
193	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Translational Oncology, 2015, 8, 288-294.	3.7	8
194	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget, 2015, 6, 40360-40369.	1.8	85
195	Recent advances in endoscopic diagnosis and treatment of gastric cancer. Journal of the Korean Medical Association, 2015, 58, 191.	0.3	2
196	The Korean guideline for gastric cancer screening. Journal of the Korean Medical Association, 2015, 58, 373.	0.3	44
197	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS Genetics, 2015, 11, e1005467.	3.5	104
198	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget, 2015, 6, 28211-28222.	1.8	57

#	Article	IF	Citations
199	Is endoscopic resection an alternative to surgery for early low-risk submucosal gastric cancers: analysis of a large surgical database. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 1614-1620.	2.4	3
200	Feasibility and Diagnostic Yield of Endoscopic Ultrasonography-Guided Fine Needle Biopsy With a New Core Biopsy Needle Device in Patients With Gastric Subepithelial Tumors. Medicine (United States), 2015, 94, e1622.	1.0	28
201	Lymphoepithelioma-like carcinoma: A distinct type of gastric cancer. Journal of Surgical Research, 2015, 194, 458-463.	1.6	27
202	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. Journal of Clinical Oncology, 2015, 33, 3130-3136.	1.6	370
203	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	30.7	1,592
204	Clinicopathological factors of multiple lateral margin involvement after endoscopic submucosal dissection for early gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 3460-3468.	2.4	15
205	Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Targeted Oncology, 2015, 10, 597-601.	3.6	39
206	Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. Endoscopy, 2015, 47, 784-793.	1.8	84
207	Preoperative Predictive Factors for Gastrointestinal Stromal Tumors: Analysis of 375 Surgically Resected Gastric Subepithelial Tumors. Journal of Gastrointestinal Surgery, 2015, 19, 631-638.	1.7	28
208	GAGE12 mediates human gastric carcinoma growth and metastasis. International Journal of Cancer, 2015, 136, 2284-2292.	5.1	16
209	Deregulation of Immune Response Genes in Patients With Epstein-Barr Virus-Associated Gastric Cancer and Outcomes. Gastroenterology, 2015, 148, 137-147.e9.	1.3	127
210	Clinical Presentation and Risk Factors for Cytomegalovirus Colitis in Immunocompetent Adult Patients. Clinical Infectious Diseases, 2015, 60, e20-e26.	5.8	70
211	Gastrointestinal stromal tumours: Correlation of modified NIH risk stratification with diffusion-weighted MR imaging as an imaging biomarker. European Journal of Radiology, 2015, 84, 33-40.	2.6	25
212	<scp>L</scp>ynchâ€like syndrome: Characterization and comparison with EPCAM deletion carriers. International Journal of Cancer, 2015, 136, 1568-1578.	5.1	40
213	Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. Gastric Cancer, 2015, 18, 618-626.	5.3	47
214	Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun. Oncotarget, 2015, 6, 20190-20203.	1.8	29
215	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget, 2015, 6, 24320-24332.	1.8	32
216	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget, 2015, 6, 25619-25630.	1.8	48

#	Article	IF	Citations
217	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget, 2015, 6, 33358-33368.	1.8	24
218	Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget, 2015, 6, 38372-38380.	1.8	47
219	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget, 2015, 6, 39028-39035.	1.8	53
220	PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors. Journal of Pathology and Translational Medicine, 2015, 49, 23-29.	1.1	9
221	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Cancer Research and Treatment, 2015, 47, 738-746.	3.0	10
222	Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters. Cancer Research and Treatment, 2015, 47, 813-822.	3.0	24
223	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN^{â„¢}).. Journal of Clinical Oncology, 2015, 33, e22173-e22173.	1.6	0
224	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	1.6	0
225	Development and validation of sensitive and selective biomarker for early detection and prognostic system of colorectal cancer using aptamer biochip.. Journal of Clinical Oncology, 2015, 33, e22124-e22124.	1.6	0
226	Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery. PLoS ONE, 2014, 9, e90133.	2.5	96
227	Endoscopic Resection for Undifferentiated Early Gastric Cancer: Focusing on Histologic Discrepancies Between Forceps Biopsy-Based and Endoscopic Resection Specimen-Based Diagnosis. Digestive Diseases and Sciences, 2014, 59, 2536-2543.	2.3	30
228	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification. Molecular Cancer Therapeutics, 2014, 13, 2527-2536.	4.1	34
229	Improved survival of gastric cancer with tumour Epsteinâ€“Barr virus positivity: an international pooled analysis. Gut, 2014, 63, 236-243.	12.1	309
230	Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an A siaâ€•P acific T ask F orce. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 297-307.	1.1	39
231	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nature Communications, 2014, 5, 5477.	12.8	166
232	Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Investigational New Drugs, 2014, 32, 535-541.	2.6	30
233	CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 1099-1106.	1.5	11
234	Poorly differentiated component in gastric pinch biopsies predicts submucosal invasion. Diagnostic Pathology, 2014, 9, 34.	2.0	5

#	Article	IF	Citations
235	Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling. Scientific Reports, 2014, 4, 3623.	3.3	25
236	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Scientific Reports, 2014, 4, 7592.	3.3	24
237	Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. Journal of Clinical Investigation, 2014, 124, 5145-5158.	8.2	105
238	High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer. PLoS ONE, 2014, 9, e111693.	2.5	34
239	Epstein-Barr virus-associated lymphoepithelioma-like early gastric carcinomas and endoscopic submucosal dissection: Case series. World Journal of Gastroenterology, 2014, 20, 1365.	3.3	21
240	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 447-56.	1.4	25
241	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. Journal of Clinical Oncology, 2014, 32, 4008-4008.	1.6	1
242	MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Modern Pathology, 2013, 26, 1632-1641.	5.5	115
243	Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Investigational New Drugs, 2013, 31, 1580-1586.	2.6	33
244	Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas. Diagnostic Pathology, 2013, 8, 121.	2.0	6
245	A Large Cohort of Consecutive Patients Confirmed Frequent HER2 Positivity in Gastric Carcinomas with Advanced Stages. Annals of Surgical Oncology, 2013, 20, 477-484.	1.5	35
246	Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. Targeted Oncology, 2013, 8, 271-280.	3.6	25
247	Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer, 2013, 119, 1627-1635.	4.1	108
248	Silent Colonic Malakoplakia in a Living-Donor Kidney Transplant Recipient Diagnosed during Annual Medical Examination. Korean Journal of Pathology, 2013, 47, 163.	1.3	9
249	Comparison of ThreeBRAFMutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples. Korean Journal of Pathology, 2013, 47, 348.	1.3	10
250	Gastrointestinal stromal tumors in children and young adults: a clinicopathologic and molecular genetic study of 22 Korean cases. Apmis, 2013, 121, 938-944.	2.0	15
251	Management Strategy for Small Duodenal Carcinoid Tumors: Does Conservative Management with Close Follow-Up Represent an Alternative to Endoscopic Treatment?. Digestion, 2013, 87, 247-253.	2.3	28
252	Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer. PLoS ONE, 2013, 8, e82770.	2.5	36

#	Article	IF	Citations
253	Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Modern Pathology, 2013, 26, 677-684.	5.5	76
254	A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers. PLoS ONE, 2013, 8, e54644.	2.5	37
255	Assessment of Gastritis Using Operative Link for Gastritis Assessment System. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2013, 13, 20.	0.4	3
256	A comparative study of telomerase activity and cytologic diagnosis in malignant ascites. Analytical and Quantitative Cytopathology and Histopathology, 2013, 35, 146-51.	0.2	4
257	Serrated adenoma of the stomach: a clinicopathologic, immunohistochemical, and molecular study of nine cases. Histology and Histopathology, 2013, 28, 453-62.	0.7	9
258	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial. Journal of Clinical Oncology, 2012, 30, 268-273.	1.6	667
259	Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation. Pathology, 2012, 44, 260-261.	0.6	2
260	Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. Pathology, 2012, 44, 18-23.	0.6	19
261	Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas. Pathology, 2012, 44, 216-220.	0.6	37
262	Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours. Pathology, 2012, 44, 460-464.	0.6	4
263	Filiform serrated adenoma: authorsâ€™ reply. Pathology, 2012, 44, 386.	0.6	0
264	Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor. Tumor Biology, 2012, 33, 1645-1651.	1.8	21
265	The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumor Biology, 2012, 33, 1573-1580.	1.8	76
266	Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta OncolÃ³gica, 2012, 51, 528-536.	1.8	29
267	Neuroendocrine tumor in gastric adenoma: a diagnostic pitfall mimicking invasive adenocarcinoma. Diagnostic Pathology, 2012, 7, 102.	2.0	13
268	Clinical usefulness of microsatellite instability test in Korean young patients with high-risk features associated with adenoma. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 378-383.	1.5	7
269	High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations. PLoS ONE, 2012, 7, e41655.	2.5	35
270	Small Submucosal Tumors of the Stomach: Differentiation of Gastric Schwannoma from Gastrointestinal Stromal Tumor with CT. Korean Journal of Radiology, 2012, 13, 425.	3.4	68

#	Article	IF	Citations
271	Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. Cancer Research and Treatment, 2012, 44, 85-96.	3.0	43
272	Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Research and Treatment, 2012, 44, 157-165.	3.0	180
273	EBV infection and mismatch repair deficiency mediated by loss of hMLH1 expression contribute independently to the development of multiple synchronous gastric carcinomas. Journal of Surgical Oncology, 2012, 106, 777-782.	1.7	9
274	Tumor size predicts survival in mucinous gastric carcinoma. Journal of Surgical Oncology, 2012, 106, 757-764.	1.7	9
275	Clinical significance of gastritis cystica profunda and its association with Epsteinâ€Barr virus in gastric cancer. Cancer, 2012, 118, 5227-5233.	4.1	30
276	Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 1333-1338.	2.3	14
277	ESOPHAGEAL PARAKERATOSIS MIMICKING ENDOSCOPIC APPEARANCE OF SUPERFICIAL ESOPHAGEAL NEOPLASTIC LESION SUCH AS DYSPLASIA. Digestive Endoscopy, 2012, 24, 117-119.	2.3	33
278	Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene. PLoS ONE, 2012, 7, e34456.	2.5	28
279	High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma. PLoS ONE, 2012, 7, e38892.	2.5	72
280	Plexiform Angiomyxoid Myofibroblastic Tumor of the Stomach: Report of Two Cases and Review of the Literature. Korean Journal of Pathology, 2012, 46, 292.	1.3	33
281	Glomus Tumor of the Stomach: A Clinicopathologic Analysis of 10 Cases and Review of the Literature. Gut and Liver, 2012, 6, 52-57.	2.9	56
282	Profiling of activated receptor tyrosine kinases in advanced gastric cancers identifies patients with poor prognosis.. Journal of Clinical Oncology, 2012, 30, 4011-4011.	1.6	8
283	Profiling of circulating tumor cells isolated from 105 metastatic gastric cancer patients revealed HER2 overexpression/activation for potential use in clinical setting.. Journal of Clinical Oncology, 2012, 30, 10535-10535.	1.6	1
284	P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients. Translational Oncology, 2011, 4, 345-349.	3.7	54
285	Endoscopic Submucosal Dissection of Early Gastric Cancer. Gut and Liver, 2011, 5, 418-426.	2.9	36
286	Molecular Features of Colorectal Hyperplastic Polyps and Sessile Serrated Adenoma/Polyps From Korea. American Journal of Surgical Pathology, 2011, 35, 1274-1286.	3.7	117
287	Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncology Reports, 2011, 25, 1517-24.	2.6	111
288	Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 293-299.	1.1	26

#	Article	IF	Citations
289	The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer, 2011, 11, 344.	2.6	76
290	DOG1 and PKC-Î¸ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Modern Pathology, 2011, 24, 866-875.	5.5	58
291	Novel mechanism of a CDH1 splicing mutation in a Korean patient with signet ring cell carcinoma. BMB Reports, 2011, 44, 725-729.	2.4	5
292	Esophageal Gland Duct Adenoma. Korean Journal of Pathology, 2011, 45, S45.	1.3	0
293	SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum. Korean Journal of Pathology, 2011, 45, 276.	1.3	0
294	Mucinous Gastric Cancer Presents with More Advanced Tumor Stage and Weaker Î²-Catenin Expression than Nonmucinous Cancer. Annals of Surgical Oncology, 2010, 17, 3053-3058.	1.5	22
295	KRAS Mutations in Traditional Serrated Adenomas From Korea Herald an Aggressive Phenotype. American Journal of Surgical Pathology, 2010, 34, 667-675.	3.7	98
296	Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. Journal of Korean Medical Science, 2010, 25, 1543.	2.5	25
297	Current Trends in the Epidemiological and Pathological Characteristics of Gastrointestinal Stromal Tumors in Korea, 2003-2004. Journal of Korean Medical Science, 2010, 25, 853.	2.5	52
298	Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virusâ€“Associated Gastric Carcinoma. Gastroenterology, 2010, 139, 84-92.e2.	1.3	162
299	Mesenteric Fibromatosis Mimicking Recurrence after Distal Gastrectomy for Gastric Cancer. Journal of Gastric Cancer, 2010, 10, 79.	2.5	1
300	Cyclooxygenase-2 Is an Independent Prognostic Factor in Gastric Carcinoma Patients Receiving Adjuvant Chemotherapy and Is Not Associated with EBV Infection. Clinical Cancer Research, 2009, 15, 291-298.	7.0	34
301	Sporadic colorectal carcinomas with lowâ€level microsatellite instability in Korea: Do they form a distinct subgroup with distinguished clinicopathological features?. Journal of Surgical Oncology, 2009, 99, 351-355.	1.7	11
302	Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridization. Pathology International, 2008, 58, 17-25.	1.3	41
303	Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Modern Pathology, 2008, 21, 1533-1541.	5.5	88
304	Prognostic Stratification of High-risk Gastrointestinal Stromal Tumors in the Era of Targeted Therapy. Annals of Surgery, 2008, 247, 1011-1018.	4.2	48
305	Multiple Gastrointestinal Stromal Tumors: Clinicopathologic and Genetic Analysis of 12 Patients. American Journal of Surgical Pathology, 2007, 31, 224-232.	3.7	102
306	Stage IV early gastric cancer: two cases with microsatellite instability. Langenbeck's Archives of Surgery, 2007, 393, 105-109.	1.9	4

#	Article	IF	Citations
307	PKCÎ¸ expression in gastrointestinal stromal tumor. Modern Pathology, 2006, 19, 1480-1486.	5.5	41
308	Progressive methylation during the serrated neoplasia pathway of the colorectum. Modern Pathology, 2005, 18, 170-178.	5.5	112
309	Composite glandular-endocrine cell carcinomas of the stomach: clinicopathologic and methylation study. Apmis, 2005, 113, 569-576.	2.0	29
310	Tracing origin of serrated adenomas with BRAF and KRAS mutations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 597-602.	2.8	42
311	Gastrointestinal Stromal Tumors in Koreans: It's Incidence and the Clinical, Pathologic and Immunohistochemical Findings. Journal of Korean Medical Science, 2005, 20, 977.	2.5	83
312	Tracing ancestry with methylation patterns: most crypts appear distantly related in normal adult human colon. BMC Gastroenterology, 2004, 4, 8.	2.0	35
313	Enhanced Stem Cell Survival in Familial Adenomatous Polyposis. American Journal of Pathology, 2004, 164, 1369-1377.	3.8	65
314	Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 491-500.	2.8	57
315	PolyA Deletions in Hereditary Nonpolyposis Colorectal Cancer. American Journal of Pathology, 2002, 160, 1503-1506.	3.8	14
316	Genetic evidence for the multi-step progression of mixed glandularâ€“neuroendocrine gastric carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 85-93.	2.8	80
317	Methylation reveals a niche: stem cell succession in human colon crypts. Oncogene, 2002, 21, 5441-5449.	5.9	100
318	Genotyping Possible Polymorphic Variants of Human Mismatch Repair Genes in Healthy Korean Individuals and Sporadic Colorectal Cancer Patients. Familial Cancer, 2002, 3, 129-137.	1.9	44
319	Low-level microsatellite instability in most colorectal carcinomas. Cancer Research, 2002, 62, 1166-70.	0.9	135
320	Evidence for two modes of allelic loss: multifocal analysis on both early and advanced gastric carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 31-38.	2.8	10
321	Prognostic implications of microsatellite genotypes in gastric carcinoma. International Journal of Cancer, 2000, 89, 378-383.	5.1	57
322	Pituitary Aspergillosis Mimicking Pituitary Tumor. American Journal of Roentgenology, 2000, 175, 1570-1572.	2.2	15
323	Comparing MR Imaging and CT in the Staging of Gastric Carcinoma. American Journal of Roentgenology, 2000, 174, 1551-1557.	2.2	159
324	Author's Correction. American Journal of Roentgenology, 2000, 175, 556-556.	2.2	0

#	Article	IF	Citations
325	Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability. , 1999, 82, 782-788.		27
326	Fractional allelic loss in gastric carcinoma correlates with growth patterns. Oncogene, 1998, 17, 2655-2659.	5.9	34
327	Gastric Carcinoma: Morphologic Classifications and Molecular Changes. , 0, , .		1
328	IL-7RÎ± ^{low} CD8 ⁺ T Cells from Healthy Individuals Are Anergic with Defective Glycolysis. SSRN Electronic Journal, 0, , .	0.4	0
329	Mycobiome analysis in fungal infected formalin-fixed and paraffin-embedded tissues for identification of pathogenic fungi: a pilot study. F1000Research, 0, 9, 758.	1.6	0